Antiprotozoans play a pivotal role in the therapeutic landscape, offering targeted solutions for diseases caused by protozoan parasites, a diverse group of microorganisms capable of causing significant morbidity and mortality in humans. Giardiasis, caused by the intestinal protozoan Giardia lamblia, finds effective treatment in drugs like metronidazole. Amoebiasis, caused by the protozoan Entamoeba histolytica, is another target for antiprotozoal therapy, with drugs like metronidazole and tinidazole serving as mainstays in clinical practice. The mechanism of action of antiprotozoans varies, with some drugs disrupting protozoan metabolic pathways, while others interfere with DNA synthesis, ultimately impeding the parasite's ability to survive and propagate. Ensuring accurate diagnosis is crucial for tailoring antiprotozoal therapy to the specific parasite involved, highlighting the importance of advanced diagnostic methods in the field of parasitology. As global travel increases, so does the risk of exposure to parasitic infections in non-endemic regions. Antiprotozoal medications, used both therapeutically and prophylactically, become integral components of travel medicine, safeguarding individuals against infections acquired in regions where protozoan parasites are prevalent. Ongoing research focuses not only on refining existing antiprotozoans but also on discovering novel compounds to combat emerging resistance and expanding the armamentarium against protozoan infections. Public awareness campaigns, emphasizing the significance of adherence to prescribed regimens and the avoidance of self-medication, further contribute to the effective use of antiprotozoal medications in the fight against parasitic diseases.